查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1866549

全球胰岛素笔市场－2025-2030年预测

Global Insulin Pens Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球胰岛素笔市场预计将从 2025 年的 69.55 亿美元成长到 2030 年的 106.56 亿美元，复合年增长率为 8.91%。

胰岛素笔市场是糖尿病管理的关键领域，提供便携、精准且易于使用的胰岛素输注装置。这些注射装置为传统的管瓶和注射器注射方式提供了一种便捷的替代方案，能够以最小的浪费输送精确剂量。全球糖尿病盛行率的上升、胰岛素笔设计的技术进步以及不同社会经济阶层的可负担性是推动市场成长的主要因素。然而，多种胰岛素混合使用的限制对市场成长构成了挑战。

本报告检验了胰岛素笔市场当前的需求、供应和销售趋势，以及影响该市场的最新发展。报告全面分析了关键驱动因素、限制因素和机会，并详细说明了区域产业趋势、政策和法规，帮助相关人员深入了解法规结构和市场动态。

我们的竞争情报是基于广泛的二手研究，包括产业协会调查、分析师报告、投资者报告、新闻稿和学术期刊，旨在识别主要企业及其收入贡献。市场规模采用由下而上和自上而下的方法计算，并经全球胰岛素笔价值链相关人员的第一手资讯检验。我们全面的市场分析整合了各种资讯来源和专有资料集，运用资料三角验证技术，提供准确的市场区隔和预测。我们透过分析叙述、图表和图形呈现洞察，以帮助读者有效率地理解。预计2024年全球市场规模约75亿美元，2030年将达128亿美元，复合年增长率为9.3%。主要参与者包括百康（Biocon）、赛诺菲（Sanofi）和诺和诺德（Novo Nordisk）。

主要亮点

  • 糖尿病流行：全球糖尿病患者人数不断增加（预计到 2024 年将达到 5.5 亿），推动了对胰岛素笔的需求。
  • 技术创新：笔的设计创新提高了精确度和易用性，推动了笔的广泛应用。
  • 价格实惠：低价钢笔提高了各个社会经济阶层的可及性，从而推动了市场成长。
  • 混合限制：无法混合多种胰岛素类型限制了其多功能性，阻碍了市场扩张。

成长要素

糖尿病盛行率的不断上升（预计到2024年全球确诊病例将增加6%）显着推动了胰岛素笔作为首选给药方式的需求。技术进步正在提升用户的便利性和依从性，例如诺和诺德公司于2024年推出的配备蓝牙连接功能的智慧胰岛素笔，可用于剂量追踪。胰岛素笔价格的降低也促进了其普及，由于学名药的竞争，新兴市场的价格下降了10%。此外，诸如印度于2024年启动的5亿美元糖尿病照护倡议等支持性医疗政策，也进一步推动了高负担地区对胰岛素笔的采用。

阻碍因素

无法在同一支胰岛素笔中混合不同类型的胰岛素限制了其多功能性，迫使需要联合治疗的患者使用多种设备。监管壁垒，包括欧盟严格的安全标准，增加了製造商的合规成本。开发中国家农村地区认知度低和获取途径有限，阻碍了市场渗透。

細項分析

按类型划分：到 2024 年，可重复使用的胰岛素笔将占 60% 的市场份额，因其成本效益和永续性而受到青睐，而一次性胰岛素笔由于其旅行便利性而稳步增长。

按应用领域划分：1 型糖尿病占比最大，但由于诊断数量的增加，2 型糖尿病正在迅速增长。

按最终用户划分：居家医疗（患者自行用药）是主导，而医院的使用正在扩大，主要面向住院患者。

区域分析

到2024年，北美将占据38%的市场份额，这主要得益于美国糖尿病高发生率和先进的医疗基础设施。亚太地区预计将以11.2%的复合年增长率实现最高增长，这主要得益于印度和中国不断增长的医疗投资和糖尿病病例。欧洲将受益于有利的监管和报销政策而维持成长。

本报告为业内人士提供关于市场趋势、监管环境和竞争动态的关键洞察。报告重点介绍了智慧胰岛素笔的创新技术和新兴市场机会，同时也探讨了配药限制和进入障碍。严谨的调查方法，结合一手和二手数据，确保了预测的可靠性，并帮助相关人员理解复杂的市场格局，优先考虑在这一重要的糖尿病管理领域的投资。

本报告的主要优势：

  • 深入分析：取得以客户群、政府政策和社会经济因素、消费者偏好、垂直产业和其他细分市场为重点的深入市场洞察，涵盖主要地区和新兴地区。
  • 竞争格局：了解主要企业采取的策略倡议，并了解透过正确的策略打入市场的潜力。
  • 市场驱动因素与未来趋势：探索动态因素和关键市场趋势，以及它们将如何塑造未来的市场发展。
  • 可执行的建议：利用洞察力为策略决策提供讯息，从而在动态环境中开拓新的业务管道和收入来源。
  • 受众范围广：对新兴企业、研究机构、顾问公司、中小企业和大型企业都有益处且经济高效。

它是用来做什么的？

产业与市场洞察、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范及其影响、新产品开发、竞争影响

分析范围

  • 历史资料（2022-2024 年）和预测资料（2025-2030 年）
  • 成长机会、挑战、供应链前景、法规结构、客户行为和趋势分析
  • 竞争对手定位、策略和市场占有率分析
  • 按业务板块和地区（国家）分類的收入成长和预测分析
  • 公司概况（策略、产品、财务资讯、关键趋势等）

目录

第一章执行摘要

第二章市场概述

  • 市场概览
  • 市场定义
  • 分析范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策和法规
  • 策略建议

第四章 技术展望

5. 全球胰岛素笔市场（按类型划分）

  • 介绍
  • 一次性胰岛素笔
  • 可重复使用的胰岛素笔

6. 全球胰岛素笔市场（依糖尿病类型划分）

  • 介绍
  • 1型糖尿病
  • 2型糖尿病

7. 全球胰岛素笔市场（以最终用户划分）

  • 介绍
  • 医院
  • 门诊手术中心
  • 居家医疗

8. 全球胰岛素笔市场依通路划分

  • 介绍
  • 零售药房
  • 医院药房
  • 网路药房

9. 全球胰岛素笔市场（按地区划分）

  • 介绍
  • 北美洲
    • 按类型
    • 依糖尿病类型
    • 最终用户
    • 透过分销管道
    • 按国家/地区
      • 美国
      • 加拿大
      • 墨西哥
  • 南美洲
    • 按类型
    • 依糖尿病类型
    • 最终用户
    • 透过分销管道
    • 按国家/地区
      • 巴西
      • 阿根廷
      • 其他的
  • 欧洲
    • 按类型
    • 依糖尿病类型
    • 最终用户
    • 透过分销管道
    • 按国家/地区
      • 英国
      • 德国
      • 法国
      • 义大利
      • 其他的
  • 中东和非洲
    • 按类型
    • 依糖尿病类型
    • 最终用户
    • 透过分销管道
    • 按国家/地区
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 其他的
  • 亚太地区
    • 按类型
    • 依糖尿病类型
    • 最终用户
    • 透过分销管道
    • 按国家/地区
      • 日本
      • 中国
      • 印度
      • 韩国
      • 台湾
      • 其他的

第十章 竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 企业合併、协议、商业合作
  • 竞争对手仪錶板

第十一章：公司简介

  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Medtronic Plc
  • Insulcloud SL
  • Sanofi SA
  • Diamesco Co., Ltd.
  • Emperra GmbH E-Health Technologies
  • Owen Mumford Ltd
  • Biocon Limited
  • BD
  • B.Braun Melsungen AG
  • Terumo Corporation

第十二章 分析方法

简介目录
Product Code: KSI061612025

The Global Insulin Pens Market is anticipated to increase from USD 6.955 billion in 2025 to USD 10.656 billion by 2030, at a CAGR of 8.91%.

The insulin pens market is a critical segment of diabetes management, offering portable, accurate, and user-friendly devices for insulin administration. These infusion devices provide a convenient alternative to traditional vial-and-syringe methods, delivering precise doses with minimal wastage. The market is driven by the rising global prevalence of diabetes, technological advancements in pen design, and affordability across diverse socioeconomic groups. However, limitations in mixing multiple insulin types pose challenges to market growth.

This research examines current trends in demand, supply, and sales, alongside recent developments shaping the insulin pens market. It provides a comprehensive analysis of key drivers, restraints, and opportunities, detailing industry trends, policies, and regulations across geographical regions to equip stakeholders with insights into the regulatory framework and market dynamics.

Competitive intelligence identifies major industry players and their revenue contributions, derived from extensive secondary research, including industry association studies, analyst reports, investor presentations, press releases, and journals. Market size for the overall sector and key segments was determined using bottom-up and top-down methodologies, validated with primary inputs from stakeholders in the global insulin pens value chain. Comprehensive market engineering integrated data from diverse sources and proprietary datasets, employing data triangulation for accurate market breakdown and forecasting. Insights are presented through analytical narratives, charts, and graphics for efficient comprehension. The global market was valued at approximately USD 7.5 billion in 2024 and is projected to reach USD 12.8 billion by 2030, growing at a CAGR of 9.3%. Key players profiled include Biocon, Sanofi, and Novo Nordisk, among others.

Key Highlights

  • Diabetes Prevalence: Rising global diabetes cases, reaching 550 million in 2024, drive demand for insulin pens.
  • Technological Advancements: Innovations in pen design enhance accuracy and ease of use, boosting adoption.
  • Affordability: Low-cost pens improve accessibility across socioeconomic groups, fueling market growth.
  • Mixing Limitations: Inability to combine multiple insulin types restricts versatility, hindering market expansion.

Growth Drivers

The increasing prevalence of diabetes, with a 6% rise in diagnoses globally in 2024, significantly boosts demand for insulin pens as a preferred administration method. Technological advancements, such as smart insulin pens with Bluetooth connectivity for dose tracking introduced by Novo Nordisk in 2024, enhance user convenience and compliance. The affordability of insulin pens, with prices dropping by 10% in emerging markets due to generic competition, broadens access. Supportive healthcare policies, such as India's USD 500 million diabetes care initiative in 2024, further drive adoption in high-prevalence regions.

Restraints

The inability to mix different insulin types in a single pen limits versatility, as patients requiring combined therapies must use multiple devices. Regulatory hurdles, including stringent safety standards in the EU, increase compliance costs for manufacturers. Limited awareness and access in rural areas of developing nations restrict market penetration.

Segmentation Analysis

By Type: Reusable insulin pens dominate with a 60% share in 2024, favored for cost-effectiveness and sustainability. Disposable pens grow steadily for convenience in travel.

By Application: Type 1 diabetes accounts for the largest share, while type 2 diabetes sees rapid growth due to rising diagnoses.

By End-User: Homecare settings lead, driven by patient self-administration, with hospitals expanding for inpatient care.

Regional Analysis

North America holds a 38% market share in 2024, driven by high diabetes prevalence and advanced healthcare infrastructure in the U.S. Asia Pacific grows at the highest CAGR of 11.2%, fueled by India and China's healthcare investments and rising diabetes cases. Europe sustains growth through supportive regulations and reimbursement policies.

This report equips industry experts with critical insights into market trends, regulatory landscapes, and competitive dynamics. It highlights opportunities in smart pen innovations and emerging markets while addressing mixing limitations and access barriers. The rigorous methodology, blending primary and secondary data, ensures reliable projections, enabling stakeholders to navigate complexities and prioritize investments in this essential diabetes management sector.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Segmentation

By Type

  • Disposable Insulin Pens
  • Reusable Insulin Pens

By Diabetes Type

  • Type I Diabetes
  • Type II Diabetes

By End-User

  • Hospitals
  • Ambulatory Surgical Centres
  • Homecare

By Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Taiwan
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL INSULIN PENS MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Disposable Insulin Pens
  • 5.3. Reusable Insulin Pens

6. GLOBAL INSULIN PENS MARKET BY DIABETES TYPE

  • 6.1. Introduction
  • 6.2. Type I Diabetes
  • 6.3. Type II Diabetes

7. GLOBAL INSULIN PENS MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Ambulatory Surgical Centres
  • 7.4. Homecare

8. GLOBAL INSULIN PENS MARKET BY DISTRIBUTION CHANNEL

  • 8.1. Introduction
  • 8.2. Retail Pharmacies
  • 8.3. Hospital Pharmacies
  • 8.4. Online Pharmacies

9. GLOBAL INSULIN PENS MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. By Type
    • 9.2.2. By Diabetes Type
    • 9.2.3. By End-User
    • 9.2.4. By Distribution Channel
    • 9.2.5. By Country
      • 9.2.5.1. United States
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. South America
    • 9.3.1. By Type
    • 9.3.2. By Diabetes Type
    • 9.3.3. By End-User
    • 9.3.4. By Distribution Channel
    • 9.3.5. By Country
      • 9.3.5.1. Brazil
      • 9.3.5.2. Argentina
      • 9.3.5.3. Others
  • 9.4. Europe
    • 9.4.1. By Type
    • 9.4.2. By Diabetes Type
    • 9.4.3. By End-User
    • 9.4.4. By Distribution Channel
    • 9.4.5. By Country
      • 9.4.5.1. United Kingdom
      • 9.4.5.2. Germany
      • 9.4.5.3. France
      • 9.4.5.4. Italy
      • 9.4.5.5. Others
  • 9.5. Middle East & Africa
    • 9.5.1. By Type
    • 9.5.2. By Diabetes Type
    • 9.5.3. By End-User
    • 9.5.4. By Distribution Channel
    • 9.5.5. By Country
      • 9.5.5.1. Saudi Arabia
      • 9.5.5.2. UAE
      • 9.5.5.3. Others
  • 9.6. Asia Pacific
    • 9.6.1. By Type
    • 9.6.2. By Diabetes Type
    • 9.6.3. By End-User
    • 9.6.4. By Distribution Channel
    • 9.6.5. By Country
      • 9.6.5.1. Japan
      • 9.6.5.2. China
      • 9.6.5.3. India
      • 9.6.5.4. South Korea
      • 9.6.5.5. Taiwan
      • 9.6.5.6. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. Novo Nordisk A/S
  • 11.2. Eli Lilly and Company
  • 11.3. Medtronic Plc
  • 11.4. Insulcloud S.L.
  • 11.5. Sanofi S.A.
  • 11.6. Diamesco Co., Ltd.
  • 11.7. Emperra GmbH E-Health Technologies
  • 11.8. Owen Mumford Ltd
  • 11.9. Biocon Limited
  • 11.10. BD
  • 11.11. B.Braun Melsungen AG
  • 11.12. Terumo Corporation

12. RESEARCH METHODOLOGY